* Q2 revenues +6% vs. ABGSCe, EBITDA strong at DKK 21.
Cereno Scientific has launched the global Phase IIb study for CS1 (EPIMODE) in pulmonary arterial hy...
Redeye updates on Embracer after Q1-results which were stronger than expected and the company reiter...
Redeye is very positively surprised by Eolus securing additional milestone payments related to Cente...
* We expect 13% organic growth in Q2 * Q2 revenues adversely impacted by lower user growth in Q1 * F...
Leaddesk provided more colour on the run-off of its third-party business, which prompts us to furthe...
Redeye retains its positive view of Transtema following a Q2 2026 report that beat our forecasts on ...
* Another strong report with org. sales +19% and EBIT +45% * '26e-'28e EBIT and EPS raised by 9-12% ...
InCoax reported a better-than-expected Q2, with sales and EBITDA ahead of our estimates despite cont...
With Q2 EBITDA in line, Leaddesk again reported top-line and ARR slightly below our estimate.
Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.
Topic: Cantourage released Q2'26 figures showing a further step-up in earnings quality.
Yesterday, LION released its Q2 results. Despite a weak quarter performance linked to the preparatio...
Q2 26 delivered a step change, with EBIT of € 19.1m (Q2 25: € 4.
DMRE Q2 results arrived slightly ahead of estimates.
Multitude reported Q2'26 results yesterday. Consumer Banking interest income came in at € 41.
* 9% organic growth (cons 2%), adj. EBITA -5% vs cons * 2026 EBITA guidance raised to "significantly...
Relais' Q2 adjusted EBITA of EUR 8m fell 14% short of Modular Finance consensus despite a 2% top-lin...
Moberg Pharma delivered a strong Q2 2026 report, with sales well ahead of Redeye's forecasts.
Q2 EBITDA missed our estimate, mainly due to higher-than-expected cash cost.